Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Moodys
Mallinckrodt
Harvard Business School
AstraZeneca

Last Updated: January 29, 2022

DrugPatentWatch Database Preview

Claims for Patent: 6,350,885

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 6,350,885
Title: Tricyclic heteroaromatics and their derivatives as inhibitors of matrix metalloproteinases
Abstract:Tricyclic heteroaromatic compounds and derivatives are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as inhibitors of matrix metalloproteinases, particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, atherosclerotic plaque rupture, aortic aneurysm, heart failure, left ventricular dilation, restenosis, periodontal disease, corneal ulceration, treatment of burns, decubital ulcers, wound healing, cancer, inflammation, pain, arthritis, osteoporosis, renal disease, or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes or other activated migrating cells, acute and chronic neurodegenerative disorders including stroke, head trauma, spinal cord injury, Alzheimer\'s disease, amyotrophic lateral sclerosis, cerebral amyloid angiopathy, AIDS, Parkinson\'s disease, Huntington\'s disease, prion diseases, myasthenia gravis, and Duchenne\'s muscular dystrophy.
Inventor(s): O\'Brien; Patrick Michael (Stockbridge, MI), Picard; Joseph Armand (Canton, MI), Sliskovic; Drago Robert (Saline, MI)
Assignee: Warner-Lambert Company (Morris Plains, NJ)
Application Number:09/719,026
Patent Claims:1. A compound of Formula I ##STR53##

wherein

n is an integer of 1 or 2;

X is --O--, or

--S;

Z is ##STR54##

wherein R.sup.7 is OR.sup.8 wherein R.sup.8 is hydrogen, alkyl,

--(CH.sub.2).sub.m -aryl wherein m is zero or an integer of 1 to 6,

--(CH.sub.2).sub.m -heteroaryl wherein heteroaryl is a 5-6 membered heteroaromatic ring having up to 3 heteroatoms selected from N, O and S, and m is as defined above,

--(CH.sub.2).sub.m -cycloalkyl having 3-7 carbon atoms in the ring wherein m is as defined above or ##STR55##

wherein R.sup.9 and R.sup.9 a are either the same or different and are hydrogen,

alky of 1-6 carbon atoms,

aryl,

arylalkyl,

heteroaryl, or

cycloalkyl;

R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are either the same or different and are

hydrogen,

fluorine,

alkyl,

alkenyl of 2-10 carbon atoms,

alkynyl of 2-10 carbon atoms,

arylalkenyl,

heteroarylalkenyl,

arylalkynyl,

heteroarylalkynyl,

--(CH.sub.2).sub.m -aryl wherein m is as defined above,

--(CH.sub.2).sub.m -heteroaryl as defined above,

--(CH.sub.2).sub.m -cycloalkyl as defined above,

--(CH.sub.2).sub.q --X.sup.a --(CH.sub.2).sub.q 1-alkyl wherein X.sup.a is O, S, SO, SO.sub.2, or NH, and q and q.sup.1 are each zero or an integer of 1 to 6, and the sum of q+q.sup.1 is not greater than six,

--(CH.sub.2).sub.q --X.sup.a --(CH.sub.2).sub.q 1-aryl wherein X.sup.a, q, and q.sup.1 are as defined above,

--(CH.sub.2).sub.q --X.sup.a --(CH.sub.2).sub.q 1-heteroaryl wherein X.sup.a, q, and q.sup.1 are as defined above, or

(CH.sub.2).sub.m --R.sup.10 wherein R.sup.10 is ##STR56##

wherein R.sup.11 is hydrogen, alkyl, aryl, arylalkyl, heteroaryl, or cycloalkyl, ##STR57##

wherein R.sup.11 is as defined above, ##STR58##

wherein R.sup.11 is as defined above, ##STR59##

wherein Y is nitrogen, oxygen, sulfur, or CH.sub.2 and

R.sup.11 and n are as defined above and m is as defined above, OR.sup.11 wherein R.sup.11 is as defined above, ##STR60##

wherein R.sup.11 and R.sup.11a are the sane or different

and are as defined above for R.sup.11, --SR.sup.11 wherein R.sup.11 is as defined above, ##STR61##

wherein R.sup.11 is as defined above, ##STR62##

wherein R.sup.11 is as defined above ##STR63##

wherein R.sup.11 is a defined above, ##STR64##

wherein R.sup.11 and R.sup.11a are the same or different

and are as defined above for R.sup.11, ##STR65##

wherein R.sup.11 is as defined above, ##STR66##

wherein R.sup.11 is as defined above, ##STR67##

wherein R.sup.11 is as defined above, or ##STR68##

wherein R.sup.11 and R.sup.11a are the same or different and are as defined above for R.sup.6, or ##STR69##

wherein R.sup.11 and R.sup.11a are as defined above; and

R.sup.5 is OH or --NHOH;

with the proviso that when n is 1, Z is ##STR70##

and R.sup.5 is OR.sup.12 wherein R.sup.12 is as defined above, then at least one of R.sup.1, R.sup.2, R.sup.3, and R.sup.4 is not hydrogen; and corresponding isomers thereof, or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 which is ##STR71##

3. The compound according to claim 1 which is ##STR72##

4. The compound according to claim 1 which is ##STR73##

5. The compound according to claim 1 which is ##STR74##

6. The compound according to claim 1 which is ##STR75##

7. The compound according to claim 1 which is ##STR76##

8. A compound selected from the group consisting of:

4-Hydroxyimino-4-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-butyric acid;

N-Hydroxy-4-hydroxyimino-4-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-butyramid e;

N-Hydroxy-4-oxo-4-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-butyramide;

4-Oxo-2-phenethyl-4-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-butyric acid;

2-[2-Oxo-2-(6,7,8,9-tetrahydro-dibenzofuran-3 -yl)-ethyl]-5-phenyl-pentanoic acid;

2-[2-Oxo-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-6-phenyl-hexanoic acid;

2-[2-Oxo-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-7-phenyl-heptanoic acid;

2-[2-Oxo-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-8-phenyl-octanoic acid;

(S) 4-Hydroxyimino-2-phenethyl-4-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-butyri c acid;

(S) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-5-phenyl -pentanoic acid;

(S) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-6-phenyl -hexanoic acid;

(S) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-7-phenyl -heptanoic acid;

(S) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-8-phenyl -octanoic acid;

(S) 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-ylmethyl)-4-oxo-4-(6,7,8,9-tetrahydro- dibenzofuran-3-yl)-butyric acid;

(S) 2-[2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-ethyl]-4-oxo-4-(6,7,8,9-tetrahy dro-dibenzofuran-3-yl)-butyric acid;

(S) 5-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-2-[2-oxo-2-(6,7,8,9-tetrahydro-dib enzofuran-3-yl)-ethyl]-pentanoic acid;

(S) 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-ylmethyl)-4-hydroxyimino-4-(6,7,8,9-te trahydro-dibenzofuran-3-yl)-butyric acid;

(S) 2-[2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-ethyl]-4-hydroxyimino-4-(6,7,8, 9-tetrahydro-dibenzofuran-3-yl)-butyric acid;

(S) 5-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-2-[2-hydroxyimino-2-(6,7,8,9-tetra hydro-dibenzofuran-3-yl)-ethyl]-pentanoic acid;

(S) 4-Oxo-4-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-2-(3,4,4-trimethyl-2,5-diox o-imidazolidin-1-ylmethyl)-butyric acid;

(S) 4-Oxo-4-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-2-[2-(3,4,4-trimethyl-2,5-d ioxo-imidazolidin-1-yl)-ethyl]-butyric acid;

(S) 2-[2-Oxo-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-5-(3,4,4-trimethy l-2,5-dioxo-imidazolidin-1-yl)-pentanoic acid;

(S) 4-Hydroxyimino-4-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-2-(3,4,4-triethyl- 2,5-dioxo-imidazolidin-1-ylmethyl)-butyric acid;

(S) 4-Hydroxyimino-4-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-2-[2-(3,4,4-trimet hyl-2,5-dioxo-imidazolidin-1-yl)-ethyl]-butyric acid;

(S) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-5-(3,4,4 -trimethyl-2,5-dioxo-imidazolidin-1-yl)-pentanoic acid;

4-Hydroxy-2-phenethyl-4-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-butyric acid;

2-[2-Hydroxy-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-5-phenyl-penta noic acid;

2-[2-Hydroxy-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-6-phenyl-hexan oic acid;

2-[2-Hydroxy-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-7-phenyl-hepta noic acid;

2-[2-Hydroxy-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-8-phenyl-octan oic acid;

4-Hydroxy-4-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-2-(3,4,4-trimethyl-2,5-d ioxo-imidazolidin-1-ylmethyl)-butyric acid;

4-Hydroxy-4-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-2-[2-(3,4,4-trimethyl-2, 5-dioxo-imidazolidin-1-yl)-ethyl]-butyric acid;

2-[2-Hydroxy-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-5-(3,4,4-trime thyl-2,5-dioxo-imidazolidin-1-yl)-pentanoic acid;

4-Oxo-4-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-butyric acid;

4-Hydroxyimino-4-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-butyric acid;

(S) 4-Oxo-2-phenethyl-4-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-but yric acid;

(S) 2-[2-Oxo-2-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-ethyl]-5-phe nyl-pentanoic acid;

(S) 2-[2-Oxo-2-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-ethyl]-6-phe nyl-hexanoic acid;

(S) 2-[2-Oxo-2-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-ethyl]-7-phe nyl-heptanoic acid;

(S) 2-[2-Oxo-2-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-ethyl]-8-phe nyl-octanoic acid;

(S) 4-Hydroxyimino-2-phenethyl-4-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen- 2-yl)-butyric acid;

(S) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-eth yl]-5-phenyl-pentanoic acid;

(S) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-eth yl]-6-phenyl-hexanoic acid;

(S) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-eth yl]-7-phenyl-heptanoic acid;

(S) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-eth yl]-8-phenyl-octanoic acid;

4-Oxo-4-(6,7,8,9-tetrahydro-dibenzothiophen-3-yl)-butyric acid;

4-Hydroxyimino-4-(6,7,8,9-tetrahydro-dibenzothiophen-3-yl)-butyric acid;

(S) 4-Oxo-4-(6,7,8,9-tetrahydro-dibenzothiophen-3-yl)-2-(3,4,4-trimethyl-2,5-d ioxo-imidazolidin-1-ylmethyl)-butyric acid;

(S) 4-Oxo-4-(6,7,8,9-tetrahydro-dibenzothiophen-3-yl)-2-[2-(3,4,4-trimethyl-2, 5-dioxo-imidazolidin-1-yl)-ethyl]-butyric acid;

(S) 2-[2-Oxo-2-(6,7,8,9-tetrahydro-dibenzothiophen-3-yl)-ethyl]-5-(3,4,4-trime thyl-2,5-dioxo-imidazolidin-1-yl)-pentanoic acid;

(S) 4-Hydroxyimino-4-(6,7,8,9-tetrahydro-dibenzothiophen-3-yl)-2-(3,4,4-trimet hyl-2,5-dioxo-imidazolidin-1-ylmethyl)-butyric acid;

(S) 4-Hydroxyimino-4-(6,7,8,9-tetrahydro-dibenzothiophen-3-yl)-2-[2-(3,4,4-tri methyl-2,5-dioxo-imidazolidin-1-yl)-ethyl]-butyric acid;

(S) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-dibenzothiophen-3-yl)-ethyl]-5-(3, 4,4-trimethyl-2,5-dioxo-imidazolidin-1-yl)-pentanoic acid;

(R) 4-Hydroxyimino-2-phenethyl-4-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-butyri c acid;

(R) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-5-phenyl -pentanoic acid;

(R) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-6-phenyl -hexanoic acid;

(R) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-7-phenyl -heptanoic acid;

(R) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-8-phenyl -octanoic acid;

(R) 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-ylmethyl)-4-oxo-4-(6,7,8,9-tetrahydro- dibenzofuran-3-yl)-butyric acid;

(R) 2-[2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-ethyl]-4-oxo-4-(6,7,8,9-tetrahy dro-dibenzofuran-3-yl)-butyric acid;

(R) 5-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-2-[2-oxo-2-(6,7,8,9-tetrahydro-dib enzofuran-3-yl)-ethyl]-pentanoic acid;

(R) 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-ylmethyl)-4-hydroxyimino-4-(6,7,8,9-te trahydro-dibenzofuran-3-yl)-butyric acid;

(R) 2-[2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-ethyl]-4-hydroxyimino-4-(6,7,8, 9-tetrahydro-dibenzofuran-3-yl)-butyric acid;

(R) 5-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-2-[2-hydroxyimino-2-(6,7,8,9-tetra hydro-dibenzofuran-3-yl)-ethyl]-pentanoic acid;

(R) 4-Oxo-4-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-2-(3,4,4-trimethyl-2,5-diox o-imidazolidin-1-ylmethyl)-butyric acid;

(R) 4-Oxo-4-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-2-[2-(3,4,4-trimethyl-2,5-d ioxo-imidazolidin-1-yl)-ethyl]-butyric acid;

(R) 2-[2-Oxo-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-5-(3,4,4-trimethy l-2,5-dioxo-imidazolidin-1-yl)-pentanoic acid;

(R) 4-Hydroxyimino-4-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-2-(3,4,4-trimethyl -2,5-dioxo-imidazolidin-1-ylmethyl)-butyric acid;

(R) 4-Hydroxyimino-4-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-2-[2-(3,4,4-trimet hyl-2,5-dioxo-imidazolidin-1-yl)-ethyl]-butyric acid;

(R) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-dibenzofuran-3-yl)-ethyl]-5-(3,4,4 -trimethyl-2,5-dioxo-imidazolidin-1-yl)-pentanoic acid;

(R) 4-Oxo-2-phenethyl-4-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-but yric acid;

(R) 2-[2-Oxo-2-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-ethyl]-5-phe nyl-pentanoic acid;

(R) 2-[2-Oxo-2-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-ethyl]-6-phe nyl-hexanoic acid;

(R) 2-[2-Oxo-2-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-ethyl]-7-phe nyl-heptanoic acid;

(R) 2-[2-Oxo-2-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-ethyl]-8-phe nyl-octanoic acid;

(R) 4-Hydroxyimino-2-phenethyl-4-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen- 2-yl)-butyric acid;

(R) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-eth yl]-5-phenyl-pentanoic acid;

(R) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-eth yl]-6-phenyl-hexanoic acid;

(R) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-eth yl]-7-phenyl-heptanoic acid;

(R) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulen-2-yl)-eth yl]-8-phenyl-octanoic acid;

(R) 4-Oxo-4-(6,7,8,9-tetrahydro-dibenzothiophen-3-yl)-2-(3,4,4-trimethyl-2,5-d ioxo-imidazolidin-1-ylmethyl)-butyric acid;

(R) 4-Oxo-4-(6,7,8,9-tetrahydro-dibenzothiophen-3-yl)-2-[2-(3,4,4-trimethyl-2, 5-dioxo-imidazolidin-1-yl)-ethyl]-butyric acid;

(R) 2-[2-Oxo-2-(6,7,8,9-tetrahydro-dibenzothiophen-3-yl)-ethyl]-5-(3,4,4-7-tri methyl-2,5-dioxo-imidazolidin-1-yl)-pentanoic acid;

(R) 4-Hydroxyimino-4-(6,7,8,9-tetrahydro-dibenzothiophen-3-yl)-2-(3,4,4-trimet hyl-2,5-dioxo-imidazolidin-1-ylmethyl)-butyric acid;

(R) 4-Hydroxyimino-4-(6,7,8,9-tetrahydro-dibenzothiophen-3-yl)-2-[2-(3,4,4-tri methyl-2,5-dioxo-imidazolidin-1-yl)-ethyl]-butyric acid;

(R) 2-[2-Hydroxyimino-2-(6,7,8,9-tetrahydro-dibenzothiophen-3-yl)-ethyl]-5-(3, 4,4-trimethyl-2,5-dioxo-imidazolidin-1-yl)-pentanoic acid; and corresponding isomers thereof; or a pharmaceutically acceptable salt thereof.

9. The pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 in admixture with a pharmaceutically acceptable excipient, diluent, or carrier.

10. The method of inhibiting a matrix metalloproteinase comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form.

11. The method of inhibiting gelatinase A comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form.

12. The method of inhibiting stromelysin-1 comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form.

13. The method of inhibiting collagenase-3 comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form.

14. The method of preventing atherosclerotic plaque rupture comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form.

15. The method of inhibiting aortic aneurysm comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form.

16. The method of inhibiting heart failure comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form.

17. The method of preventing restenosis comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form.

18. The method of controlling periodontal disease comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form.

19. The method of treating corneal ulceration comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form.

20. The method of treating burns comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form.

21. The method of treating decubital ulcers comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form.

22. The method of treatment for healing wounds comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form.

23. The method of treating arthritis comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form.

24. The method of treating osteoporosis comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form.

25. The method of treating inflammation and pain comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form.

26. The method of treating renal disease comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form.

27. The method of treating left ventricular dilation comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form.

28. The pharmaceutical composition comprising a compound according to claim 1 in admixture with a pharmaceutically acceptable excipient, diluent, or carrier.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Moodys
Colorcon
Merck
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.